GS Regimen as the First-line Chemotherapy in Chinese Advanced PC Patients

Zhejiang University

Status: Completed

Conditions: Chemotherapy Effect; Chemotherapeutic Toxicity; Pancreatic Cancer

Treatments: Drug: GS

Study type: Observational

Funder types: Other

Identifiers

NCT03869294

ZYYY-PAC1

Details and patient eligibility

About

Gemcitabine plus S-1 (GS) prolonged progression-free survival (PFS) and greatly improved objective response rate (ORR) as well as disease control rate (DCR) of Asian patients with locally advanced and metastatic pancreatic cancer (PC). However, limited data of GS regimen exist on the efficacy and safety in the treatment of Chinese patients with advanced PC. To assess the efficacy and safety of gemcitabine plus S-1 (GS regimen) as the first-line chemotherapy in Chinese patients with advanced PC, we designed this prospective study.

Enrollment: 96 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1.Histologically confirmed pancreatic adenocarcinoma 2.Locally advanced or metastatic PC 3.Chemotherapy-naïve 4.ECOG performance status of 0 or 1 5. An adequate bone marrow, liver function and kidney function

Exclusion criteria

• 1.Age ≥80 years 2.Brain metastasis 3.With other malignancies 4.Chronic diarrhea, cardiac disease, pregnancy or breast feeding

Trial design

96 participants in 1 patient group

LAPC or MPC patients with GS first-line chemotherapy

Treatment:

Drug: GS